Galenica AG
Galenica AG operates as a healthcare service provider in Switzerland and internationally. It operates in two segments, Products & Care, and Logistics & IT. The Products & Care segment operates pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at h… Read more
Galenica AG (GALNF) - Net Assets
Latest net assets as of June 2025: $1.45 Billion USD
Based on the latest financial reports, Galenica AG (GALNF) has net assets worth $1.45 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.06 Billion) and total liabilities ($1.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.45 Billion |
| % of Total Assets | 47.21% |
| Annual Growth Rate | 19.45% |
| 5-Year Change | 47.32% |
| 10-Year Change | 498.73% |
| Growth Volatility | 42.88 |
Galenica AG - Net Assets Trend (2013–2024)
This chart illustrates how Galenica AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Galenica AG (2013–2024)
The table below shows the annual net assets of Galenica AG from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.55 Billion | +5.20% |
| 2023-12-31 | $1.48 Billion | +18.07% |
| 2022-12-31 | $1.25 Billion | +1.28% |
| 2021-12-31 | $1.23 Billion | +17.12% |
| 2020-12-31 | $1.05 Billion | +5.38% |
| 2019-12-31 | $999.54 Million | +7.06% |
| 2018-12-31 | $933.60 Million | +8.37% |
| 2017-12-31 | $861.51 Million | +157.78% |
| 2016-12-31 | $334.20 Million | +28.94% |
| 2015-12-31 | $259.19 Million | +7.88% |
| 2014-12-31 | $240.26 Million | +9.36% |
| 2013-12-31 | $219.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galenica AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 642.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.56 Billion | 100.48% |
| Common Stock | $5.00 Million | 0.32% |
| Total Equity | $1.55 Billion | 100.00% |
Galenica AG Competitors by Market Cap
The table below lists competitors of Galenica AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
iRhythm Technologies Inc
NASDAQ:IRTC
|
$3.75 Billion |
|
Anji Microelectronics Tech Co Ltd
SHG:688019
|
$3.75 Billion |
|
Westlake Chemical Corporation
NYSE:WLK
|
$3.76 Billion |
|
Adani Energy Solutions Limited
NSE:ADANIENSOL
|
$3.76 Billion |
|
Broadstone Net Lease Inc
NYSE:BNL
|
$3.74 Billion |
|
Kontoor Brands Inc
NYSE:KTB
|
$3.74 Billion |
|
AGL Energy Ltd
PINK:AGLXY
|
$3.74 Billion |
|
Teleperformance SE
PINK:TLPFF
|
$3.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galenica AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,471,419,000 to 1,548,694,000, a change of 77,275,000 (5.3%).
- Net income of 182,951,000 contributed positively to equity growth.
- Dividend payments of 110,173,000 reduced retained earnings.
- Share repurchases of 9,703,000 reduced equity.
- New share issuances of 4,107,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $182.95 Million | +11.81% |
| Dividends Paid | $110.17 Million | -7.11% |
| Share Repurchases | $9.70 Million | -0.63% |
| Share Issuances | $4.11 Million | +0.27% |
| Other Changes | $10.09 Million | +0.65% |
| Total Change | $- | 5.25% |
Book Value vs Market Value Analysis
This analysis compares Galenica AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.34x to 2.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $4.61 | $75.25 | x |
| 2015-12-31 | $5.08 | $75.25 | x |
| 2016-12-31 | $6.59 | $75.25 | x |
| 2017-12-31 | $17.47 | $75.25 | x |
| 2018-12-31 | $18.90 | $75.25 | x |
| 2019-12-31 | $20.13 | $75.25 | x |
| 2020-12-31 | $21.16 | $75.25 | x |
| 2021-12-31 | $24.73 | $75.25 | x |
| 2022-12-31 | $25.01 | $75.25 | x |
| 2023-12-31 | $29.49 | $75.25 | x |
| 2024-12-31 | $31.04 | $75.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galenica AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.81%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.67%
- • Asset Turnover: 1.28x
- • Equity Multiplier: 1.98x
- Recent ROE (11.81%) is below the historical average (18.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 35.53% | 2.90% | 1.65x | 7.42x | $58.79 Million |
| 2015 | 31.93% | 2.78% | 1.68x | 6.82x | $55.72 Million |
| 2016 | 25.30% | 2.77% | 1.52x | 6.02x | $50.43 Million |
| 2017 | 13.86% | 3.78% | 1.75x | 2.10x | $33.08 Million |
| 2018 | 15.87% | 4.65% | 1.70x | 2.00x | $54.60 Million |
| 2019 | 12.58% | 3.78% | 1.50x | 2.22x | $25.64 Million |
| 2020 | 16.45% | 4.95% | 1.54x | 2.16x | $67.52 Million |
| 2021 | 13.66% | 4.37% | 1.47x | 2.13x | $44.93 Million |
| 2022 | 13.26% | 4.11% | 1.51x | 2.14x | $40.57 Million |
| 2023 | 11.80% | 4.63% | 1.25x | 2.03x | $26.46 Million |
| 2024 | 11.81% | 4.67% | 1.28x | 1.98x | $28.08 Million |
Industry Comparison
This section compares Galenica AG's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $1,282,977,105
- Average return on equity (ROE) among peers: -5.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galenica AG (GALNF) | $1.45 Billion | 35.53% | 1.12x | $3.75 Billion |
| Accendra Health Inc (ACH) | $314.40 Million | 8.91% | 1.75x | $22.90K |
| Arjo AB (publ) (ARRJF) | $6.88 Billion | 10.78% | 1.12x | $491.29 Million |
| Cardinal Health Inc (CAH) | $255.60 Million | 13.15% | 1.57x | $50.81 Billion |
| Cencora Inc. (COR) | $4.01 Billion | 11.02% | 2.01x | $62.31 Billion |
| Cosmos Health Inc. (COSM) | $36.04 Million | -51.45% | 0.83x | $8.90 Million |
| EDAP TMS SA (EDAP) | $50.05 Million | 1.40% | 0.54x | $115.72 Million |
| Empro Group Inc. Ordinary shares (EMPG) | $741.21K | -42.90% | 4.10x | $9.16 Million |
| Energy Management International Inc (ENMI) | $-362.21K | 0.00% | 0.00x | $383.13K |
| Exlites Holdings International Inc (EXHI) | $-84.27 | 0.00% | 0.00x | $574.58K |